Cardiovascular Drugs and Therapy

, Volume 21, Issue 2, pp 77–79

Cerebrovascular Events After Discontinuation of Rofecoxib Treatment



  1. 1.
    Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709–11.PubMedCrossRefGoogle Scholar
  2. 2.
    Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Curfman GD, Morrissey S, Drazen JM. Expression of concern: bombardier et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis, N Engl J Med 2000;343:1520–8. N Engl J Med 2005;353:2813–4.Google Scholar
  4. 4.
    Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092–102.PubMedCrossRefGoogle Scholar
  5. 5.
    FDA—Department of Health and Human Services. Joint meeting of the arthritis advisory committee and the drug safety and risk management advisory committee. Accessed March 1, 2007.
  6. 6.
    Merck. APPROVe Extension Statistical Package. Accessed March 1, 2007.
  7. 7.
    McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, Fitzgerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999;96:272–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Kudryashov SA, Tertov VV, Orekhov AN, Geling NG, Smirnov VN. Regression of atherosclerotic manifestations in primary culture of human aortic cells: effects of prostaglandins. Biomed Biochim Acta 1984;43:S284–S286.PubMedGoogle Scholar
  9. 9.
    Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002;296:539–41.PubMedCrossRefGoogle Scholar
  10. 10.
    Andersohn F, Schade R, Suissa S, Garbe E. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study. Stroke 2006;37:1725–30.PubMedCrossRefGoogle Scholar
  11. 11.
    Fitzgerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003;2:879–90.PubMedCrossRefGoogle Scholar
  12. 12.
    Serebruany VL, Malinin AI, Bhatt DL. Paradoxical rebound platelet activation after painkillers cessation: missing risk for vascular events? Am J Med 2006;119:707 e. 11–6.Google Scholar
  13. 13.
    Bogaty P, Brophy JM, Noel M, Boyer L, Simard S, Bertrand F et al. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study. Circulation 2004;110:934–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Fischer LM, Schlienger RG, Matter CM, Jick H, Meier CR. Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction. Arch Intern Med 2004;164:2472–6.PubMedCrossRefGoogle Scholar
  15. 15.
    EMEA—European Medicines Agency. Public CHMP Assessment report for medicinal products containing non-selective non steroidal anti-inflammatory drugs (NSAIDs). Accessed March 1, 2007.
  16. 16.
    Lagakos SW. Time-to-event analyses for long-term treatments—the APPROVe trial. N Engl J Med 2006;355:113–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Chen LC, Ashcroft DM. Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials. J Clin Pharm Ther 2006;31:565–76.PubMedCrossRefGoogle Scholar
  18. 18.
    Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Charité—Universitaetsmedizin BerlinInstitute of Clinical Pharmacology and ToxicologyBerlinGermany

Personalised recommendations